Determining the best treatment for renal cell carcinoma in young patients

Karakiewicz and colleagues1 have demonstrated that age at diagnosis appears to be an independent prognostic factor for cancer-specific survival in patients with renal cell carcinoma (RCC), confirming findings reported by other investigators.2–4 Unlike other sites such as the colon and prostate, younger patients presenting with RCC appear to have a better prognosis than older patients. Although one must interpret the results of retrospective studies with caution (e.g., perhaps younger patients received more detailed staging and follow-up imaging, or perhaps they were more likely to receive adjuvant therapy if needed), the data seem compelling. This survival benefit suggests that an age-tailored approach to managing RCC is important. Given the favourable survival data for younger patients, the importance of nephron-sparing surgery increases, even in cases where it may not be imperative. This is particularly true when combined with data suggesting that long-term renal function is superior following nephron-sparing surgery5 and cancer-specific survival is equivalent to open surgery. Although partial nephrectomy remains the gold standard form of nephron-sparing surgery, the role for other renal ablative technologies such as radio-frequency ablation, cryotherapy, high-intensity focused ultrasound and the Gamma Knife remains to be defined — particularly in the treatment of the disease in younger patients. Minimizing patient morbidity while maximizing survival and long-term cure rates is important to all patients, but it is doubly important in younger patients.